Goeschen K, Saling E
Geburtshilfe Frauenheilkd. 1982 Nov;42(11):810-8. doi: 10.1055/s-2008-1037164.
From April 1, 1978 to March 31, 1979 199 patients with a high risk pregnancy and a Bishop score of less than 7 among a total number of deliveries of 2075 needed induction of labour for medical indications. In 143 patients oxytocin infusions were given, in 56 patients PGF2 alpha infusions were given. It was shown that PGF2 alpha by infusion showed no advantages over oxytocin infusions. The duration of labour and delivery was not shortened. The foetal morbidity was not decreased. The incidence of Caesarean section remained unchanged at a high 32% and the incidence of vaginal operative delivery remained high at 50%. The incidence of post-partum acidosis in the newborn remained at around 14%. Therefore induction of labour was tried on the unripe cervix in the following 12 months with the intra-cervical application of 0.4 mg. PGE2 gel in 202 patients. The same criteria of high risk pregnancies and unripe cervices were used in the following 12 months. In contradistinction to the induction of labour with oxytocin infusion or PGF2 alpha infusion statistically very significant differences in favor of PGE2 gel were found. The foetal morbidity during labour, the duration of labour, the mode of delivery, the neonatal morbidity and the post-partum maternal condition regarding haemoglobin and pyrexia were improved. The low incidence of Caesarean section at 8% and the low incidence of post-partum acidosis in the newborn was especially noteworthy in the PGE2 gel group. Although excellence of prenatal care is essential for the improvement of obstetric results the timely termination of a high risk pregnancy is the second important step to reduce maternal and foetal morbidity. PGE2 gel intracervically improves this second step.
1978年4月1日至1979年3月31日期间,在2075例分娩中,有199例高危妊娠且Bishop评分低于7分的患者因医学指征需要引产。143例患者接受了催产素静脉滴注,56例患者接受了前列腺素F2α静脉滴注。结果表明,静脉滴注前列腺素F2α并不比催产素静脉滴注有优势。产程和分娩时间并未缩短,胎儿发病率也未降低。剖宫产率仍高达32%,阴道助产率仍高达50%。新生儿产后酸中毒发生率仍在14%左右。因此,在接下来的12个月里,对未成熟宫颈进行引产,202例患者宫颈内应用了0.4毫克前列腺素E2凝胶。在接下来的12个月里,采用了相同的高危妊娠和未成熟宫颈标准。与催产素静脉滴注或前列腺素F2α静脉滴注引产不同,发现前列腺素E2凝胶在统计学上有非常显著的差异,且有利于前列腺素E2凝胶组。产时胎儿发病率、产程、分娩方式、新生儿发病率以及产后母亲血红蛋白和发热情况均有所改善。前列腺素E2凝胶组剖宫产率低至8%以及新生儿产后酸中毒发生率低尤其值得注意。尽管优质的产前护理对于改善产科结局至关重要,但及时终止高危妊娠是降低母婴发病率至关重要的第二步。宫颈内应用前列腺素E2凝胶改善了这第二步。